In vitro antibiotic susceptibility testing of Brucella isolates from Egypt between 1999 and 2007 and evidence of probable rifampin resistance

Annals of Clinical Microbiology and Antimicrobials

Volumn 11, Issue , 2012, Pages

  Abdel Maksoud, Mohamed ^a   House, Brent ^a   Wasfy, Momtaz ^a   Abdel Rahman, Bassem ^a   Pimentel, Guillermo ^a   Roushdy, Gehan ^b   Dueger, Erica ^a,c  

^a US Naval Medical Research Unit No 3 Egypt   (Egypt)

^b Central Public Health Laboratory   (Egypt)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Brucella; Brucellosis; Ceftriaxone; E test; Egypt; MIC; Rifampin

Indexed keywords

ANTIBIOTIC AGENT; CEFTRIAXONE; CIPROFLOXACIN; COTRIMOXAZOLE; DOXYCYCLINE; GENTAMICIN; RIFAMPICIN; STREPTOMYCIN; TETRACYCLINE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM CULTURE; BACTERIUM ISOLATE; BLOOD CULTURE; BRUCELLA; BRUCELLOSIS; CONTROLLED STUDY; EGYPT; EPSILOMETER TEST; FEVER; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRACTICE GUIDELINE;

ANTI-BACTERIAL AGENTS; BRUCELLA; BRUCELLOSIS; DRUG RESISTANCE, BACTERIAL; EGYPT; GENOTYPE; HUMANS; MICROBIAL SENSITIVITY TESTS; RIFAMPIN;

EID: 84865340606     PISSN: None     EISSN: 14760711     Source Type: Journal    
DOI: 10.1186/1476-0711-11-24     Document Type: Article

References (25)

1. Memish ZA, Balkhy HH. Brucellosis and international travel. J Travel Med 2004, 11:49-55.
2. Marianelli C, Graziani C, Santangelo C, Xibilia MT, Imbriani A, Amato R, Neri D, Cuccia M, Rinnone S, Di Marco V, Ciuchini F. Molecular epidemiological and antibiotic susceptibility characterization of Brucella isolates from humans in Sicily. Italy. J. Clin. Microbiol 2007, 45:2923-2928.
3. Samaha H, Al-Rowaily M, Khoudair RM, Ashour HM. Multicenter study of Brucellosis in Egypt. Emerg Infect Dis 2008, 14:1916-1918. 10.3201/eid1412.071452, 2634613, 19046520.
4. Afifi S, Earhart K, Azab MA, Youssef FG, El Sakka H, Wasfy M, Mansour H, El Oun S, Rakha M, Mahoney F. Hospital-based surveillance for acute febrile illness in Egypt: a focus on community-acquired blood stream infections. AmJTrop Med Hyg 2005, 73:392-399.
5. Refai MK. Brucellosis in animals and man in Egypt. Egypt J Vet Sci 2003, 37:1-31.
6. Jennings GJ, Hajjeh RA, Girgis FY, Fadeel MA, Maksoud MA, Wasfy MO, El-Sayed N, Srikantiah P, Luby SP, Earhart K, Mahoney F. Brucellosis as a cause of acute febrile illness in Egypt. Trans R Soc Trop Med Hyg 2007, 101:707-713. 10.1016/j.trstmh.2007.02.027, 17442354.
7. World Health Organization Brucellosis in humans and animals. Treatment of brucellosis in humans. WHO/CDS/EPR 2006, 7:36-38. World Health Organization.
8. Turkmani A, Ioannidis A, Christidiou A, Psaroulaki A, Loukaides F, Tselentis Y. In vitro susceptibility of Brucella melitensis isolates to eleven antibiotics. Annals Clin. Microbiol. Antimicrob 2006, 5:24-29.
9. El Miedany YM, El Gaafary M, Baddour M, Ahmed I. Human brucellosis: do we need to revise our therapeutic policy?. J Rheumatol 2003, 30:2666-2672.
10. Garcia-Rodrigez JA, Munoz Belilidio JL, Fresnadillo MJ, Trujillano I. In vitro activities of new Macrolides and Rifepentine against Brucella spp. Antimcrob. Agents Chemother 1993, 37:911-913.
11. Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH. Manual of clinical microbiology, 7th ed. American society for microbiology 1999, 625-631.
12. Bricker BJ, Halling SM. Differentiation of Brucella abortus bv. 1, 2, and 4, Brucella melitensis, Brucella ovis, and Brucella suis bv. 1 by PCR. J Clin Microbiol 1994, 32:2660-2666. 264138, 7852552.
13. Clinical and Laboratory Standards Institute Performance Standards for Antimicrobial Susceptibility Testing. Twentieth informational Supplement, CLSI document M 100-S20 2010, Wayne, PA, USA, Clinical and Laboratory Standards Institute.
14. El-Olemy GM, Atta AA, Mahmoud WH, Hamzah EG. Brucellosis in man--II. Isolation of the causative organisms with special reference to blood picture and urine constituents. Dev Biol Stand 1984, 56:573-578.
15. Maves RC, Castillo R, Guillen A, Espinosa B, Meza R, Espinoza N, Nunez G, Sanchez L, Chacaltana J, Cepeda D, Gonzalez S, Hall ER. Antimicrobial susceptibility of Brucella melitensis isolates in Peru. Antimicrob Agents Chemother 2011, 55:1279-1281. 10.1128/AAC.00979-10, 3067062, 21199926.
16. Baykam N, Esener H, Ergonul O, Eren S, Celikbas AK, Dokuzoguz B. In vitro antimicrobial susceptibility of Brucella species. Intern J Antimicrob Agents 2004, 23:405-407.
17. Bodur H, Balaban N, Aksaray S, Yetener V, Akinci E, Coplan A, Erbay A. Biotypes and antimicrobial susceptibilities of Brucella isolates. Scand J Infect Dis 2003, 35:337-338. 10.1080/00365540310008348, 12875523.
18. Lopez-Merino A, Contreras-Rodriguez A, Migranas-Ortiz R, Orrantia-Gradin R, Hernandez-Oliva GM, Guttierrez-Rubio AT, Cardenosa O. Susceptibility of Mexican brucella isolates to moxifloxacin, ciprofloxacin and other antimicrobials used in the treatment of human brucellosis. Scand J Infect Dis 2004, 36:636-638. 10.1080/00365540410020767, 15370648.
19. Memish Z, Mah MW, Al Mahmoud S, Al Shaalan M, Khan MY. Brucella bacteraemia: clinical and laboratory observation in 160 patients. J Infect 2000s, 40:59-63.
20. Kose S, Kilic S, Ozbel Y. Identification of Brucella species isolated from proven Brucellosis Patient in Izmir Turkey. J. Basic Micobiol 2005, 45:323-327.
21. Tanyel E, Coban AY, Koruk ST, Simsek H, Hepsert S, Cirit OS, Tulek N. Actual antibiotic resistant pattern of Brucella melitensis in central Anatolia. Saudi Med J 2007, 28:1239-1242.
22. Trujillano-Martin I, Garcia-Sanchez E, Martinez IM, Fresnadillo MJ, Garcia-Sanchez JE, Garcia-Rodriguez JA. In vitro activities of six new fluoroquinolones against Brucella melitensis. Antimicrob Agents Chemother 1999, 43:194-195. 89049, 9869594.
23. Aliskan H, Turunc T, Demiroglu YZ, Colakoglu S, Arslan H. Investigation of in vitro antibiotic susceptibility of Brucella melitensis. Mikrobiyol Bul 2008, 42:125-129.
24. Dimitrov TS, Panigrahi D, Emara M, Al-Nakkas A, Awni F, Passadilla R. Incidence of Bloodstream Infections in a Specialty Hospital in Kuwait: 8-Years Experience. Med Princ Pract 2005, 14:417-421. 10.1159/000088115, 16220016.
25. Ronland PS, Wright CG. Topical Aminoglycoside cochlear otoxicity. Otoxicity, by Ronald & Rutka (eds.) 2004, 114. BC Decker Inc, Hamilton, Ontario.